Wolstencroft PW, et al. - This trial incorporated the characterization of the cutaneous disease course in adult patients with dermatomyositis. Despite aggressive systemic therapy, clinical remission appeared to be relatively uncommon and patients with anti–melanoma differentiation-associated protein 5 antibodies displayed a lesser likelihood of entering the clinical remission during a 3-year follow-up period. Mycophenolate mofetil compared favorably with other treatment options. However, it was evidenced that a major proportion of patients with dermatomyositis presented with a skin disease that was not adequately managed with standard-of-care therapies.